Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing or treating obesity comprising phospholipase A2 as active ingredient

A technology of active ingredients and compositions, applied in the field of compositions for improving obesity, can solve the problems of increased stability and side effects of administration time length, and achieve the effect of reducing inflammatory macrophages

Pending Publication Date: 2022-03-01
双亥生命科学株式会社
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, drug therapy has problems in terms of stability and side effects due to increased length of administration, and thus there is a demand for the development of new therapeutic agents for obesity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating obesity comprising phospholipase A2 as active ingredient
  • Composition for preventing or treating obesity comprising phospholipase A2 as active ingredient
  • Composition for preventing or treating obesity comprising phospholipase A2 as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Example 1: Effect of bvPLA2 on reducing adipose tissue weight and body weight

[0131] The obesity-improving effect of bvPLA2 was evaluated by changes in adipose tissue weight and body weight in mice with HFD-induced obesity.

[0132] More specifically, C57BL / 6 mice were fed ND or HFD for 15 weeks. After 4 weeks of feeding with ND or HFD, mice were injected with PLA2 or PBS starting at week 5 ( figure 1 A). Subsequently, adipose tissue and body weight were measured according to bvPLA2 injection or no injection.

[0133] The result is as figure 1 As shown in , the body weight of the HFD group was higher than that of the ND group, and the HFD+PLA2 group showed a significant decrease in body weight compared with the HFD group without PLA2 administration ( figure 1 B and 1C). However, no changes in food intake were observed in all groups ( figure 1 D). In addition, epididymal WAT and inguinal WAT weights were significantly increased in the HFD group but greatly decre...

Embodiment 2

[0135] Example 2: Effect of bvPLA2 on body weight and adipose tissue weight of CD206-deficient and regulatory T-cell-deficient mice

[0136] To investigate the immunomodulatory effect of bvPLA2, CD206-deficient (CD206- / -) mice lacking mannose receptors were used.

[0137] More specifically, by combining with the above experimental schedule ( figure 1 A) The body weight and adipose tissue weight of CD206- / - mice were measured by the same method.

[0138] The result is as figure 2 As shown in , there were no significant changes in body weight and adipose tissue weight between the HFD and HFD+PLA2 groups ( figure 2 A to 2D).

[0139] To investigate the association between bvPLA2 and regulatory T cells, regulatory T cell depletion was performed in mice by injecting anti-mouse CD25 antibody (clone PC61) every 3 days. Rat IgG was used as a control.

[0140] The result is as figure 2 As shown in , body weight was significantly reduced in the IgG+PLA2-induced obesity mouse gr...

Embodiment 3

[0142] Example 3: Hepatotoxicity / nephrotoxicity reducing effect of bvPLA2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for improving obesity, which contains phospholipase A2 as an active ingredient, one of the main components of bee venom, and more specifically, to: a pharmaceutical composition for preventing or treating obesity, which contains phospholipase A2 as an active ingredient; a functional health food composition for preventing or improving obesity, comprising phospholipase A2 as an active ingredient; a feed composition; a method for preventing or treating obesity, the method comprising a step of administering to a subject a composition comprising phospholipase A2 as an active ingredient; and the use of a composition comprising phospholipase A2 as an active ingredient for preventing or treating obesity. A composition for reducing inflammatory macrophages and for preventing or treating obesity, comprising phospholipase A2 as an active ingredient, which is a substance of the present invention and a main component of bee venom, can be effectively used as a pharmaceutical composition.

Description

technical field [0001] The present disclosure relates to a composition for improving obesity containing phospholipase A2, one of the main components of bee venom, as an active ingredient, and more specifically relates to: a composition for preventing Or a pharmaceutical composition for treating obesity; a health functional food composition containing phospholipase A2 as an active ingredient for preventing or improving obesity; a feed composition; a method for preventing or treating obesity, the The method includes administering to a subject a composition comprising phospholipase A2 as an active ingredient; and use of the composition comprising phospholipase A2 as an active ingredient for preventing or treating obesity. Background technique [0002] Obesity, a representative symptom of excessive accumulation of fat in the body, is classified as one of the major metabolic diseases and is a serious health problem faced by countries around the world. At least 300 million people...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/46A61P3/04A61K35/64A23L33/17A23K20/147
CPCA61K38/465A61P3/04A61K35/64C12Y301/01004A23L33/17A23K20/147A23V2002/00A23V2200/332A23V2250/54A23K20/189A61P3/00A61P3/10A61P13/12
Inventor 裵玹秀郑显珠
Owner 双亥生命科学株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com